<div id="readability-page-1">DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) told shareholders it is entering 2026 with advancing cancer programs, improving clinical signals, and a cash runway that management says extends into …</div>

APRE

<p>賓夕法尼亞州道爾斯敦 — Aprea Therapeutics, Inc.（納斯達克：APRE）告訴股東，公司將在 2026 年進入時，癌症項目正在推進，臨牀信號改善，管理層表示現金流將持續到……</p>

Aprea 表示，隨着癌症試驗的進展和資金的延續，2026 年將迎來一個轉折點